An Indian pharmaceutical manufacturer, Curis Lifesciences Limited, has acquired a 49.95% stake in a Nigerian-incorporated company as part of efforts to establish a pharmaceutical business in the country.
The company, based in Gujarat, India, is partnering with Eurosun Pharmaceuticals through a Nigerian venture, Curosun Pharmaceutical Nig Ltd, to register, market and distribute its products locally.
Curis disclosed the investment in August 2026, saying it had acquired ordinary shares representing 49.95% of the Nigerian company. The arrangement gives the Indian manufacturer a substantial ownership interest in its Nigerian operations rather than relying solely on an export and distribution agreement.
The partnership was initially agreed in December 2025, when Curis appointed Eurosun as the exclusive exporter and distributor of its pharmaceutical products in Nigeria. Under the arrangement, Eurosun would handle product registration, regulatory approvals and market development, while Curis would supply the medicines.
In its 2025/26 annual report, Curis said the Nigerian venture was established to register, market, distribute and sell its pharmaceutical products. The company said it would contribute its manufacturing and product-development capabilities, while Eurosun would provide local regulatory and distribution expertise.
The Nigerian expansion is part of Curis’s broader effort to grow its international business, particularly in emerging markets.
What the company makes
Curis manufactures pharmaceutical formulations, including tablets, capsules, oral liquid medicines, creams, gels, ointments and sterile ophthalmic ointments.
Its business also includes contract manufacturing, in which it produces medicines for other pharmaceutical companies, and the development and marketing of its own branded products.
The company operates a manufacturing facility in Sanand, Gujarat. Its annual report says it has a portfolio of 943 approved products and operates across several dosage forms.
Curis has historically relied heavily on contract manufacturing and licensing arrangements, with its own-brand export business accounting for a relatively small share of its revenue.
Its Nigerian strategy is intended to expand the contribution of its own-brand products through local registration and commercialisation.
In a March 2026 investor presentation, the company said it was working with Eurosun to register more than 20 products in Nigeria. It projected that the country could eventually contribute between 5% and 10% of its revenue, although this remains a target rather than established sales.
Regulatory clearance and market entry
Curis already has a presence in Nigeria’s pharmaceutical regulatory system.
The National Agency for Food and Drug Administration and Control (NAFDAC) lists Curis Lifesciences Pvt. Limited, India, in its foreign pharmaceutical manufacturing inspection database.
The agency’s listing records a satisfactory Good Manufacturing Practice (GMP) status following an inspection in June 2025. The approval covers tablets, capsules, oral liquid medicines, sterile ophthalmic ointments and creams, and is valid until June 2028.
The manufacturing-site clearance does not mean all the company’s medicines are automatically approved for sale in Nigeria. Individual products must meet the applicable registration requirements before commercialisation.
Curis said in its annual report that it was progressing with product registrations alongside Eurosun and would begin commercialising its products after securing the necessary regulatory approvals.
The company has not publicly disclosed the full list of products intended for the Nigerian market, the investment value of its Nigerian venture or when commercial sales are expected to begin.
The extent to which the arrangement will translate into local pharmaceutical production, employment and technology transfer also remains unclear.
Discover more from Pluboard
Subscribe to get the latest posts sent to your email.